Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.
作者信息
Ciccolini Joseph, Benzekry Sébastien, Lacarelle Bruno, Barbolosi Dominique, Barlési Fabrice
机构信息
SMARTc Unit, Pharmacokinetics Laboratory, Inserm S_911 CRO2 Aix Marseille University, and La Timone University Hospital of Marseille, 13000 Marseille, France;
Modelling, Control, and Computations Unit, Institut National de Recherche en Informatique et en Automatique, 33000 Bordeaux, France;
出版信息
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16.
Abstract
摘要
相似文献
1
Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.提高抗血管生成与化疗联合治疗的疗效：是时候借助数学建模支持了。
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16.
2
Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.对西科利尼等人的回复：利用数学建模预测癌症患者对抗血管生成疗法的反应。
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3454. doi: 10.1073/pnas.1507225112. Epub 2015 Jun 16.
3
In focus: non-small cell lung cancer: E1505.聚焦：非小细胞肺癌：E1505。
Clin Adv Hematol Oncol. 2007 Mar;5(3):206-8.
4
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.卡铂和纳米白蛋白结合型紫杉醇抗VEGF治疗后肿瘤血管生成改善与肺癌患者生存率相关。
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20.
5
Angiogenesis inhibition in the treatment of lung cancer.血管生成抑制在肺癌治疗中的应用
Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2.
6
[Are antiangiogenic antibodies universal for solid tumor?].抗血管生成抗体对实体瘤是否具有普遍性？
Bull Cancer. 2007 Jul;94 Spec No:S191-6.
7
Antiangiogenic agents in breast cancer.乳腺癌中的抗血管生成药物。
Cancer Invest. 2007 Oct;25(7):518-26. doi: 10.1080/07357900701648516.
8
Chemotherapy and antiangiogenic agents in non-small-cell lung cancer.非小细胞肺癌中的化疗与抗血管生成药物
Clin Lung Cancer. 2007 Feb;8 Suppl 2:S68-73. doi: 10.3816/clc.2007.s.004.
9
Targeting tumor neovasculature in non-small-cell lung cancer.靶向非小细胞肺癌中的肿瘤新生血管。
Crit Rev Oncol Hematol. 2013 May;86(2):130-42. doi: 10.1016/j.critrevonc.2012.10.003. Epub 2012 Nov 15.
10
Novel angiogenesis inhibitors in nonsmall cell lung cancer.非小细胞肺癌中的新型血管生成抑制剂
Curr Opin Oncol. 2015 Mar;27(2):79-86. doi: 10.1097/CCO.0000000000000166.
引用本文的文献
1
Computational Multi-Scale Modeling of Drug Delivery into an Anti-Angiogenic Therapy-Treated Tumor.药物递送进入抗血管生成治疗后肿瘤的计算多尺度建模
Cancers (Basel). 2023 Nov 17;15(22):5464. doi: 10.3390/cancers15225464.
2
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer.贝伐珠单抗与培美曲塞/顺铂给药的非小细胞肺癌最佳时间安排。
CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):577-586. doi: 10.1002/psp4.12415. Epub 2019 May 9.
3
Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.重新审视贝伐珠单抗联合细胞毒药物的治疗方案：实验性非小细胞肺癌的概念验证研究。
CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):42-50. doi: 10.1002/psp4.12265. Epub 2017 Dec 7.
4
Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.使用贝伐单抗治疗的卵巢癌患者的结局和预后：台湾北部一家三级医院的6年经验。
PLoS One. 2017 May 3;12(5):e0175703. doi: 10.1371/journal.pone.0175703. eCollection 2017.
5
Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine.转移性甲状腺癌对放射性碘治疗反应的建模：个性化医疗的概念验证研究
Oncotarget. 2017 Jun 13;8(24):39167-39176. doi: 10.18632/oncotarget.16637.
6
Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.对西科利尼等人的回复：利用数学建模预测癌症患者对抗血管生成疗法的反应。
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3454. doi: 10.1073/pnas.1507225112. Epub 2015 Jun 16.
本文引用的文献
1
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.卡铂和纳米白蛋白结合型紫杉醇抗VEGF治疗后肿瘤血管生成改善与肺癌患者生存率相关。
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20.
2
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.贝伐珠单抗诱导肿瘤血管正常化会阻碍抗体摄取。
Cancer Res. 2013 Jun 1;73(11):3347-55. doi: 10.1158/0008-5472.CAN-12-3518. Epub 2013 Apr 11.
3
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.用抗血管生成疗法使肿瘤血管正常化：联合治疗的新范例。
Nat Med. 2001 Sep;7(9):987-9. doi: 10.1038/nm0901-987.
Zotero 插件